Status:
RECRUITING
Esophageal Varices Prophylaxis in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab
Lead Sponsor:
Tanta University
Conditions:
Esophageal and/or Gastric Varices
Hepatocellular Carcinoma (HCC)
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal of this prospective cohort study is to evaluate the progression of esophagogastric varices in patients treated with atezolizumab-bevacizumab. Assess the efficacy of primary prophylaxis of sma...
Eligibility Criteria
Inclusion
- Patients with confirmed advanced HCC (Diagnosed by two imaging modalities or liver biopsy) eligible for atezolizumab-bevacizumab therapy.
- Patients with preserved liver function (compensated Child-Pugh A if there is underlying cirrhosis).
- Patients with performance status ≤2 at staging work-up.
- Patients with no or grade 1 non-risky esophageal varices on pretreatment endoscopic examination.
Exclusion
- Child-Pugh class C patients.
- Patients with performance status \>2 at staging work-up.
- Vascular disorders and arterial hypertension.
- Severe autoimmune disorders.
- Patients who lost follow-up.
- Pregnant or breastfeeding women.
- Unwilling to participate in our study.
Key Trial Info
Start Date :
February 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2026
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT06961526
Start Date
February 15 2025
End Date
July 1 2026
Last Update
May 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tanta University Hospitals
Tanta, Gharbyea, Egypt, 31516